Publications in collaboration with researchers from Hospital Vega Baja (25)

2024

  1. Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 9, pp. 643-652

  2. Optimizing periprosthetic fracture management and in-hospital outcome: insights from the PIPPAS multicentric study of 1387 cases in Spain

    Journal of Orthopaedics and Traumatology, Vol. 25, Núm. 1

  3. Predictors of outcomes after internal fixation of periprosthetic femoral hip fractures Subgroup analysis of the peri-implant and peri-prosthetic fractures Spanish registry (PIPPAS)

    Injury, Vol. 55, Núm. 10

  4. Use of Triple Therapy in Asthma: The GEMAFORUM V Task Force

    Journal of investigational allergology & clinical immunology, Vol. 34, Núm. 4, pp. 257-260

2023

  1. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

    Circulation, Vol. 147, Núm. 19, pp. 1436-1443

  2. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328

2022

  1. Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study

    Medicine (United States), Vol. 101, Núm. 24, pp. E29252

  2. Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting

    Reumatologia Clinica, Vol. 18, Núm. 10, pp. 567-573

  3. Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry

    ESC Heart Failure, Vol. 9, Núm. 4, pp. 2189-2198

  4. Recommendations for the management of critically ill patients with COVID-19 in Intensive Care Units

    Medicina Intensiva, Vol. 46, Núm. 2, pp. 81-89

2021

  1. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience

    Journal of Clinical Lipidology, Vol. 15, Núm. 4, pp. 584-592

2020

  1. Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review

    Reumatologia Clinica, Vol. 16, Núm. 5P1, pp. 324-332

  2. Expert consensus statement on heart failure with reduced ejection fraction: beyond the guidelines

    Revista Espanola de Cardiologia Suplementos, Vol. 20, Núm. SB, pp. 1-46

  3. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

2019

  1. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study

    Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996

2017

  1. Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)

    Circulation, Vol. 135, Núm. 22, pp. 2133-2144

2016

  1. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome

    Critical Care, Vol. 20, Núm. 1

2013

  1. Treatment adherence and unmet needs at hospital pharmacy for the care of Spanish patients with multiple sclerosis

    European Journal of Hospital Pharmacy, Vol. 20, Núm. 1, pp. 20-25

2012

  1. Impact of apathy on health-related quality of life in recently diagnosed Parkinson's disease: The ANIMO study

    Movement Disorders, Vol. 27, Núm. 2, pp. 211-218

2009

  1. Sustained ventricular arrhythmias in unstable angina patients: Results of the ARIAM database

    Medical Science Monitor, Vol. 15, Núm. 6